MIBC: Clinical Trials

4 recruiting, 2 not yet recruiting. 1 Phase 2, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	1	Not yet recruiting 1
Phase 3	1	Recruiting 1

Follow MIBC: new trials by email Literature Review of MIBC trials Research Report on MIBC

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC) This is a non-interventional, observational, prospective study. - NMIBC, MIBC		Not yet recruiting	Bladder Cancer Advocacy Network	1400	2027-03-01	2026-10-26
Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC Gemcitabine, Toripalimab, Disitamab Vedotin (RC48) - MIBC	Phase 3	Recruiting	Zhiquan Hu	170	2026-07-01	2026-07-09
Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as Perioperative Systemic Therapy for Urothelial Carcinoma Urothelial Cancer, MIBC		Recruiting	Comprehensive Cancer Center Munich (CCCM)	79	2026-06-01	2026-10-13
Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI Multiparametric Magnetic Resonance Imaging (mpMRI) - MIBC, mpMRI		Recruiting	Assiut University	39	2025-08-29	2025-10-02
Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients gemcitabine + cisplatine - Mibc, Muscle Invasive Bladder Cancer	Phase 2	Not yet recruiting	Fundación de investigación HM	70	2024-12-01	2024-10-04
A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD) NMIBC, MIBC		Recruiting	Peking University First Hospital	300	2024-03-01	2025-05-28

Narrower conditions

Non-Muscle Invasive Bladder Neoplasms (2)  ·  Driving Under the Influence (1)  ·  Neoplasms (1)  ·  Peripheral Nervous System Diseases (1)  ·  Urinary Bladder Neoplasms (1)

Broader conditions

Carcinoma (2)  ·  Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Male Urogenital Diseases (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms by Site (2)  ·  Neoplasms, Glandular and Epithelial (2)  ·  Urinary Bladder Diseases (2)  ·  Urogenital Diseases (2)  ·  Urogenital Neoplasms (2)  ·  Urologic Diseases (2)  ·  Urologic Neoplasms (2)  ·  Behavior (1)  ·  Criminal Behavior (1)  ·  Dangerous Behavior (1)

Interventions

Gemcitabine (2)  ·  Cystectomy (1)  ·  Multiparametric Magnetic Resonance Imaging (1)  ·  Prospective Studies (1)  ·  RC48 antibody (1)  ·  disitamab vedotin (1)  ·  toripalimab (1)

Sponsors

Assiut University (1)  ·  Bladder Cancer Advocacy Network (1)  ·  Comprehensive Cancer Center Munich (CCCM) (1)  ·  Fundación de investigación HM (1)  ·  Peking University First Hospital (1)  ·  Zhiquan Hu (1)

Countries

China (2)  ·  Egypt (1)  ·  Germany (1)  ·  Spain (1)  ·  United States (1)

Top investigators

Amr Darwish, Lecturer (1)  ·  Yair Lotan, MD (1)

Results publications

PMID 33109737, PMID 41193372